about
Mutational profiling of kinases in glioblastoma.Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) GeneMeningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications.Paradoxical role of SOX2 in gastric cancerβ1 Integrins as Therapeutic Targets to Disrupt Hallmarks of CancerSingle-cell analysis tools for drug discovery and developmentmiRNA interventions serve as 'magic bullets' in the reversal of glioblastoma hallmarksThe TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeuticsReverse phase protein arrays in signaling pathways: a data integration perspectivePathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine GliomaNF-κB and STAT3 in glioblastoma: therapeutic targets coming of ageChallenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategiesMolecular characteristics of pediatric high-grade gliomasRole of SOX family of transcription factors in central nervous system tumorsEpigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumorsEph receptors as therapeutic targets in glioblastomaMolecular markers for colorectal cancer screeningHeterogeneity of epidermal growth factor receptor signalling networks in glioblastomaContemporary murine models in preclinical astrocytoma drug developmentDomino: Extracting, Comparing, and Manipulating Subsets Across Multiple Tabular Datasets.Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like CellsMONGKIE: an integrated tool for network analysis and visualization for multi-omics data.Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesThe prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysisT-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesTargeting SOX2 as a Therapeutic Strategy in GlioblastomaAccelerating glioblastoma drug discovery: Convergence of patient-derived models, genome editing and phenotypic screeningTelomere maintenance and the etiology of adult gliomaWhat next for newly diagnosed glioblastoma?Current Therapeutic Advances Targeting EGFR and EGFRvIII in GlioblastomaEmerging technologies for studying DNA methylation for the molecular diagnosis of cancerMolecular heterogeneity in glioblastoma: potential clinical implicationsPhage display discovery of novel molecular targets in glioblastoma-initiating cellsThe epidemiology of glioma in adults: a "state of the science" reviewTraumatic brain injury and subsequent glioblastoma development: Review of the literature and case reportsRelation between Established Glioma Risk Variants and DNA Methylation in the TumorSystematic genetic analysis identifies Cis-eQTL target genes associated with glioblastoma patient survival
P2860
Q21261249-167C6829-BB0B-45A9-A196-6204AD90BA0FQ26739925-8324B7E6-4BAA-4887-A616-83E262E6132FQ26741529-D61BA3FD-382B-41D6-A15F-D840F7B25616Q26749130-070CF06A-6E8A-41F7-82BD-033584A14973Q26774789-3EE4739A-CC63-4CB8-B374-8D3F44CFFE6EQ26775754-206CD74A-2074-4B8A-AB7D-9A8328DBE325Q26781836-2A720429-1A0F-49EA-B036-D8189B19C603Q26795601-4A4325BE-1855-42EE-ABA1-122BBB53A0ADQ26799716-F18DC2BB-7E3C-4E32-8FF2-D56FBFDEF4A0Q26801528-CCC10073-6FD8-4CB0-AE55-25F55FEC8D24Q26830388-3EA9BF4F-A2B9-465D-A8D0-28E997DA2B7DQ26852366-E21C0DA0-6547-4D1B-9FDE-2229D01D5E98Q26860786-45E602FF-2332-4686-8F08-51F195A970F5Q26860974-303003AD-266D-4945-B2C3-06EA70C11D0BQ26864920-A9CE785F-413B-4910-9A3D-C7084512BC36Q27000196-EF32A1AA-B351-4572-AF06-387B0C07F28DQ27010063-54F6020A-F6DD-4B3B-925A-4EBA2369ABA4Q27013006-959FCE07-98A6-4CA9-9D02-30978CD6170BQ27026937-78689081-727C-43D8-89C5-D47484050C08Q27316282-869E00E4-ADF7-4103-975C-014AA4075DD9Q27320024-2D82C2E2-F5F1-4DD2-9C90-4BF48112F0CCQ27335661-EF7666A2-E04F-432F-93D2-DBD99652953EQ27853175-C3A25556-4BA6-49D6-968A-6BF06F90ABB3Q27853199-15360076-F2F2-49DC-967F-31E851ACD626Q27853347-B5EC26E1-76AD-4CF6-BA4C-66E3E6318CE5Q28066926-12154A48-1038-4E37-AE4C-AD6621AC08D8Q28074595-CBA10769-5624-4C41-9C8F-C3FF00ADD278Q28074619-412DD428-8093-4D46-BF7B-AEEFA2F84916Q28079501-8DCB106C-9866-4EE2-8429-DFBAC0422102Q28080068-C85E30A1-A602-41E8-9823-109B80A8E89CQ28084275-CE528942-DC2E-4A4A-A121-B5FC9F8EE4D3Q28086839-3850F814-94E6-4DAE-8AD8-ED5522D00B2AQ28087306-84DD6DE8-3F2C-4C04-9721-9ACECA4445F9Q28087759-E1F4B7DE-2023-40C9-9629-B7DC5CB3FBC6Q28088605-967E7C7D-226C-4B95-890F-FDB95E2AF1D5Q28240138-DA5B9373-2DCA-4521-B536-B60B58D568B9Q28387839-7F922671-34F6-4F8B-9E89-21855FDC321DQ28388337-29D40868-A1B8-43E6-93EE-7C8B344C4607Q28392499-4783D3BD-69F1-4B63-AF3D-04EEE5662D8BQ28392623-0D0B819F-336A-4295-91B2-EBEC9FC8AFDE
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The somatic genomic landscape of glioblastoma
@ast
The somatic genomic landscape of glioblastoma
@en
The somatic genomic landscape of glioblastoma
@nl
type
label
The somatic genomic landscape of glioblastoma
@ast
The somatic genomic landscape of glioblastoma
@en
The somatic genomic landscape of glioblastoma
@nl
prefLabel
The somatic genomic landscape of glioblastoma
@ast
The somatic genomic landscape of glioblastoma
@en
The somatic genomic landscape of glioblastoma
@nl
P2093
P2860
P50
P3181
P1433
P1476
The somatic genomic landscape of glioblastoma
@en
P2093
Abhijit Guha
Andrew Sloan
Benito Campos
Brady Bernard
Brian P O'Neill
Chang-Jiun Wu
D Neil Hayes
Daniel J Weisenberger
David W Andrews
Gaetano Finocchiaro
P2860
P304
P3181
P356
10.1016/J.CELL.2013.09.034
P407
P50
P577
2013-10-10T00:00:00Z